Why and how immunohistochemistry should now be used to screen for the BRAFV600E status in metastatic melanoma? The experience of a single institution (LCEP, Nice, France)

Long, E.; Ilie, M.; Lassalle, S.; Butori, C.; Poissonnet, G.; Washetine, K.; Mouroux, J.; Lespinet, V.; Lacour, J. P.; Taly, V.; Laurent-Puig, P.; Bahadoran, P.; Hofman, V.; Hofman, P.

Published in

Wiley, Journal of the European Academy of Dermatology and Venereology, 12(29), p. 2436-2443, 2015

DOI: 10.1111/jdv.13332

Tools

Export citation

Search in Google Scholar

Why and how immunohistochemistry should now be used to screen for the BRAFV600E status in metastatic melanoma? The experience of a single institution (LCEP, Nice, France)

Journal article published in 2015 by E. Long, M. Ilie, S. Lassalle, C. Butori, G. Poissonnet, K. Washetine, J. Mouroux, V. Lespinet, J. P. Lacour, V. Taly

, P. Laurent-Puig, P. Bahadoran, V. Hofman, P. Hofman

This paper is made freely available by the publisher.

Full text: Download

Preprint: archiving allowed

Upload

Postprint: archiving restricted

Upload

Published version: archiving forbidden

Policy details

Data provided by

Published in

Links

Tools

Why and how immunohistochemistry should now be used to screen for the BRAFV600E status in metastatic melanoma? The experience of a single institution (LCEP, Nice, France)